1443 studies found for:    "Anticoagulants"
Show Display Options
Rank Status Study
1 Completed Anticoagulant Clinics and Vitamin K Antagonists
Condition: Blood Coagulation Disorders
Intervention: Drug: Anticoagulant (warfarin, acenocoumarol, fluindione)
2 Active, not recruiting D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
Conditions: Deep Vein Thrombosis;   Pulmonary Embolism
Interventions: Other: Discontinue anticoagulant therapy (Negative d-dimer);   Other: Continue on anticoagulant therapy (positive d-dimer)
3 Recruiting Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance
Condition: Ischemic Stroke
Intervention: Drug: oral anticoagulants
4 Recruiting START-Register: Survey on Anticoagulated Patients Register
Conditions: Atrial Fibrillation;   Venous Thromboembolism;   Heart Valve Diseases or Prosthesis;   Other Heart or Peripheral Vascular Diseases Leading to Chronic Anticoagulation
Interventions: Drug: Anticoagulants;   Drug: anticoagulants
5 Not yet recruiting SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial
Condition: Atrial Fibrillation
Intervention: Drug: anticoagulant by physician criteria
6 Not yet recruiting Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase
Conditions: Lymphoma;   Acute Lymphoblastic Leukemia
Interventions: Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
7 Recruiting EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban(Xarelto,BAY59-7939);   Drug: Standard Anticoagulant Therapy
8 Not yet recruiting Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
Conditions: Anticoagulants;   Thromboembolism;   Hemorrhage
Interventions: Other: Measurement of Plasma Concentrations of NOACs;   Genetic: Identification of ABCB1 polymorphisms coding for P-gp
9 Completed Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Condition: Atrial Fibrillation
Intervention: Drug: Non-coumadin Oral Anticoagulant
10 Completed Assays for and Reversal of New Anticoagulants
Conditions: Atrial Fibrillation;   Osteoarthritis of the Knee;   Osteoarthritis of the Hip
Intervention:
11 Recruiting Novel Oral Anticoagulants in Stroke Patients
Conditions: Ischemic Stroke,;   Intracranial Hemorrhage,
Intervention:
12 Completed Anticoagulant and Antiplatelet Agents in Patients Undergoing Vitreoretinal Surgery
Condition: Retinal Detachment
Intervention:
13 Recruiting Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
Conditions: Myeloma;   Venous Thromboembolism
Intervention: Drug: Apixaban
14 Recruiting Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
Conditions: Ischemic Stroke;   Patent Foramen Ovale;   Atrial Septal Aneurysm;   Migraine
Interventions: Drug: aspirin;   Drug: Antivitamins K;   Device: Devices for PFO closure
15 Completed Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
Condition: Thrombosis, Venous
Interventions: Drug: dalteparin;   Drug: enoxaparin;   Drug: fondaparinux;   Drug: unfractionated heparin
16 Unknown  Anticoagulant Treatments and Percutaneous Coronary Angioplasty
Condition: Coronary Artery Disease
Interventions: Drug: clopidogrel + aspirin;   Drug: heparin + clopidogrel + aspirin;   Drug: enoxaparin + clopidogrel + aspirin;   Drug: bivalirudin + clopidogrel + aspirin
17 Terminated Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections
Condition: Infection; Dialysis Catheter
Interventions: Drug: NAC/Tigecycline/Heparin combination lock solution;   Drug: Standard anticoagulant (Heparin or Citrate)
18 Enrolling by invitation Comparison of Accidents and Their Circumstances With Oral Anticoagulants
Conditions: Cardiovascular Complications;   Hemorrhagic Disorders;   Embolism and Thrombosis
Intervention: Other: Follow up
19 Suspended Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
Condition: Colon Cancer
Intervention: Drug: recombinant nematode anticoagulant protein c2 (rNAPc2)
20 Completed Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy
Condition: Bleeding
Intervention: Drug: Antithrombotics

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years